Jacob George
Corporate Officer/Principal presso The Hebrew University of Jerusalem
Posizioni attive di Jacob George
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| The Hebrew University of Jerusalem | Corporate Officer/Principal | - | - |
Storia della carriera di Jacob George
Precedenti posizioni note di Jacob George
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Chemomab Ltd.
 Chemomab Ltd. BiotechnologyHealth Technology ChemomAb Ltd. develops novel chemokine blocking therapies for inflammatory and fibrotic disorders. It specializes in the development of proprietary monoclonal antibodies, directed towards novel targets, for the treatment of immune-mediated and fibrotic disorders including orphan indications. The company was founded by Adi Mor and Jacob George in 2011 and is headquartered Tel Aviv, Israel. | Direttore/Membro del Consiglio | 01/01/2011 | - |
| Fondatore | 01/01/2011 | - | |
| NOTABLE LABS, LTD. | Direttore Tecnico/Scientifico/R&S | 27/01/2000 | - |
| Fondatore | 27/01/2000 | - |
Formazione di Jacob George
| Technion-Israel Institute of Technology | Doctorate Degree |
Statistiche
Distribuzione geografica
| Israele | 5 |
Posizioni
| Founder | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
Settori
| Health Technology | 3 |
| Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 2 |
|---|---|
Vascular Biogenics Ltd.
 Vascular Biogenics Ltd. BiotechnologyHealth Technology Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of next-generation, targeted medicines for difficult-to-treat medical conditions. Its product candidates are built off of its platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel. | Health Technology |
Chemomab Ltd.
Chemomab Ltd. BiotechnologyHealth Technology ChemomAb Ltd. develops novel chemokine blocking therapies for inflammatory and fibrotic disorders. It specializes in the development of proprietary monoclonal antibodies, directed towards novel targets, for the treatment of immune-mediated and fibrotic disorders including orphan indications. The company was founded by Adi Mor and Jacob George in 2011 and is headquartered Tel Aviv, Israel. | Health Technology |
- Borsa valori
- Insiders
- Jacob George
- Esperienza
